Last reviewed · How we verify
NCT07532538: ML-HNC-Risk
A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions
trial in Hypopharyngeal Cancer in 3,000 participants. Not yet recruiting.
30 November 2029
Quick facts
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 30 April 2026 |
| Primary completion | 30 November 2029 |
| Estimated completion | 30 November 2030 |
| Sites | 1 location across China |
Conditions studied
- Hypopharyngeal Cancer — all drugs for Hypopharyngeal Cancer →
- Laryngeal Cancer — all drugs for Laryngeal Cancer →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Who can join
Adults 18 to 100, any sex, with Hypopharyngeal Cancer or Laryngeal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to develop and validate a clinical prediction model for the risk of head and neck cancerous lesions using deep learning combined with AI algorithms, based on multi-center clinical data.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07532538
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypopharyngeal Cancer
Currently open trials in the same condition.
- NCT06039631 — Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer · Phase 2 · recruiting
- NCT05894070 — The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer · recruiting
- NCT05375266 — Immune Biomarker Study for Head and Neck Cancer · recruiting
Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials
Trials by the same sponsor.
- NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
- NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting
- NCT07372612 — Flow-diverting Devices for the Treatment of Middle Cerebral Artery Bifurcation Aneurysms · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07532538 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07532538.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing